RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

We've talked about this before. They don't have to bring that to shareholders at all. Now--would they consider that sufficient to bring to the BOD? Since the BOD is meeting this Friday, I suspect that one of the topics will be the current state of offers for the whole or for pieces. I don't think 40 cents will entice the BOD--not unless there is much worse news about the SA trial than I expect to see.

BTW--one of the fallacies being circulated is that Cortex probably has an offer on the table that they are errantly sidestepping in hopes of positive SA results. Unlikely. When there is a trial that is pending, that could produce data (positive or negative) relevant to the valuation of an asset, Big Pharmas tend to take a 'wait-and-see' approach. A BD group does not want to sign a deal that then may look foolish to their superiors because negative data came out shortly thereafter. There have been exceptions--GSK signed a deal with Targacept when a pain trial was being completed, which subsequently failed. However, what the CEO told me later was that this failure had been anticipated, and thus was not a surprise to GSK.

The SA trial would not have any effect on ADHD or HI negotiations, but for anything respiratory, it's likely that Pharma will want to see those data first, just as Cortex does.

NeuroInvestment